Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

We recently compiled a list of the Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a look at ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) traded up 6.8% on Tuesday following a better than expected earnings announcement. The stock traded as high as $3.01 and last traded at $3.05.

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the ...

ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago. These figures are ...

Reports Q4 revenue $7.55M, consensus $9.51M. “The first quarter of 2025 has been an inflection point for the Company with multiple milestones ...

CULVER CITY, Calif., March 03, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code ...

Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from ...